NEVVI Medicare utilization intelligence
or

← back

Provider profile

FUENTES BAYNE, HARRY MD

Medical Oncology · NPI 1194131995 · ROCHESTER, MN

1
Groups
36
Codes · 2024
34,518
Disclosed services

FUENTES BAYNE, HARRY is a Medical Oncology in ROCHESTER, MN, a member of 1 medical group, who billed 36 distinct codes to Medicare Part B in 2024.

Groups: MAYO CLINIC (ROCHESTER, MN)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

34,518
disclosed services
36
codes billed to Medicare Part B
Prior year · CY2023 22,144 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1453 Injection, fosaprepitant, 1 mg
J9267 Injection, paclitaxel, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
J9041 Injection, bortezomib, 0.1 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
96375 Injection of additional new drug or substance into vein
J9190 Injection, fluorouracil, 500 mg
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J9000 Injection, doxorubicin hydrochloride, 10 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J0640 Injection, leucovorin calcium, per 50 mg
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J1200 Injection, diphenhydramine hcl, up to 50 mg
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
J3490 Unclassified drugs
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or
96372 Injection of drug or substance under skin or into muscle
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96411 Administration of additional new drug or substance into vein using push technique
J7030 Infusion, normal saline solution , 1000 cc
96361 Infusion into a vein for hydration, each additional hour
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.